Literature DB >> 10182193

Cost effectiveness of coronary heart disease prevention strategies in adults.

A D Brown1, A M Garber.   

Abstract

Although risk-factor modification has gained wide acceptance as an effective approach to the prevention of coronary heart disease (CHD), health planners, physicians and patients confront considerable uncertainty over the most appropriate and efficient preventive strategies. Some preventive approaches are both inexpensive and effective; others are expensive while their effectiveness is slight or unproven. Effectiveness varies with an individual's age, gender and other risk factors. Information provided by a cost-effectiveness analysis can clarify the value of alternative strategies for CHD prevention in specific populations, thereby helping to choose among them. It does so by producing a standard measure of value--the cost per year of life saved (YLS) or cost per quality-adjusted life-year (QALY) saved--that reveals which of several alternative interventions provides the greatest health benefit from a given expenditure. This article summarises the extensive literature on the cost effectiveness of CHD prevention with an emphasis on primary prevention. Published work indicates that smoking-cessation programmes, particularly those that rely on counselling with or without nicotine supplements, are highly cost effective in many settings. Although the evidence is limited, exercise programmes also appear to be cost effective. The detection and treatment of hypertension is highly cost effective, particularly when inexpensive drugs with proven effectiveness, such as diuretics or beta-blockers, are used. Hormone-replacement therapy is a cost-effective approach to CHD prevention in most postmenopausal women, although direct clinical trial data are lacking and it is uncertain which hormone preparation is best. Cholesterol reduction is a cost-effective strategy for the prevention of CHD in individuals without other treatable risk factors who are at very high risk of developing CHD. For individuals with multiple CHD risk factors, the choice of risk-modification strategies is complex and depends upon the interactions of risk and the relative costs of treating each risk.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10182193     DOI: 10.2165/00019053-199814010-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  72 in total

Review 1.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

2.  Measures of clinical efficacy. Cost-effectiveness calculations in the diagnosis and treatment of hypertensive renovascular disease.

Authors:  B J McNeil; P D Varady; B A Burrows; S J Adelstein
Journal:  N Engl J Med       Date:  1975-07-31       Impact factor: 91.245

3.  Health status and hypertension: a population-based study.

Authors:  W F Lawrence; D G Fryback; P A Martin; R Klein; B E Klein
Journal:  J Clin Epidemiol       Date:  1996-11       Impact factor: 6.437

Review 4.  Clinical misconceptions dispelled by epidemiological research.

Authors:  W B Kannel
Journal:  Circulation       Date:  1995-12-01       Impact factor: 29.690

5.  Attitudes of women toward hormone therapy and prevention of heart disease.

Authors:  L Pilote; M A Hlatky
Journal:  Am Heart J       Date:  1995-06       Impact factor: 4.749

6.  Economics of a reduction in smoking: case study from Heartbeat Wales.

Authors:  C J Phillips; M J Prowle
Journal:  J Epidemiol Community Health       Date:  1993-06       Impact factor: 3.710

7.  Effect of antihypertensives on sexual function and quality of life: the TAIM Study.

Authors:  S Wassertheil-Smoller; M D Blaufox; A Oberman; B R Davis; C Swencionis; M O Knerr; C M Hawkins; H G Langford
Journal:  Ann Intern Med       Date:  1991-04-15       Impact factor: 25.391

8.  Differences in the treatment of myocardial infarction between the United States and Canada. A survey of physicians in the GUSTO trial.

Authors:  L Pilote; C Granger; P W Armstrong; D B Mark; M A Hlatky
Journal:  Med Care       Date:  1995-06       Impact factor: 2.983

9.  Health promotion in primary care: modelling the impact of intervention on coronary heart disease and stroke.

Authors:  P D Pharoah; S P Sanderson
Journal:  J Public Health Med       Date:  1995-06

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  5 in total

1.  Changing healthcare capital-to-labor ratios: evidence and implications for bending the cost curve in Canada and beyond.

Authors:  Eric Nauenberg
Journal:  Int J Health Care Finance Econ       Date:  2014-08-17

Review 2.  Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.

Authors:  G L Plosker; C I Dunn; D P Figgitt
Journal:  Drugs       Date:  2000-11       Impact factor: 9.546

3.  Economic benefits of amlodipine treatment in patients with coronary artery disease.

Authors:  Roman Casciano; John J Doyle; John Chen; Steve Arikian; Julian Casciano; Heather Kugel; Raul Arocho
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

4.  Global, regional and national burden of emergency medical diseases using specific emergency disease indicators: analysis of the 2015 Global Burden of Disease Study.

Authors:  Junaid Razzak; Mohammad Farooq Usmani; Zulfiqar A Bhutta
Journal:  BMJ Glob Health       Date:  2019-03-30

5.  Cost-effectiveness evaluation of a collaborative patient education hypertension intervention in Utah.

Authors:  Justin G Trogdon; Barbara Larsen; David Larsen; Wendy Salas; Matt Snell
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-03       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.